Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H30N7OS.K |
| Molecular Weight | 539.737 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4
InChI
InChIKey=OCKQGXSJNJCCDO-UHFFFAOYSA-N
InChI=1S/C27H30N7OS.K/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26;/h7-10,12-15H,5-6,11,16-17H2,1-4H3;/q-1;+1
| Molecular Formula | K |
| Molecular Weight | 39.0983 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C27H31N7OS |
| Molecular Weight | 501.646 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23811571, http://www.boryung.co.kr/eng/product/mainProduct.do
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23811571, http://www.boryung.co.kr/eng/product/mainProduct.do
Fimasartan is a angiotensin II receptor antagonist which was developed in Korea for the treatment of hypertension. The drug is available in different forms: Kanarb, Dukarb (in combination with Amlodipine), Tuvero (in combination with Rosuvastatin). Fimasartan was tested to be effective in Mexican and Russian population and now is being tested in the USA.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. | 2011 Nov |
|
| Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions via nuclear factor-kappa B and activator protein-1 inactivation. | 2013 |
|
| The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics. | 2014 May |
Patents
Sample Use Guides
Fimasartan is taken as a single oral dose of 60-mg tablet or a single 30-mg intravenous (IV) infusion.
Route of Administration:
Other
Rabbit thoracic aorta cells were incubated with different concentrations of fimasartan ((0.1, 1, 10 nM). At those concentrations fimasartan caused nonparallel rightward shifts in the concentration–contractile response curve to Ang II with a significant reduction in the maximal contractile response to 96.6, 47 and 18%, respectively.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:50:37 GMT 2023
by
admin
on
Sat Dec 16 10:50:37 GMT 2023
|
| Record UNII |
T2ICP7GBBN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
T2ICP7GBBN
Created by
admin on Sat Dec 16 10:50:37 GMT 2023 , Edited by admin on Sat Dec 16 10:50:37 GMT 2023
|
PRIMARY | |||
|
100000168911
Created by
admin on Sat Dec 16 10:50:37 GMT 2023 , Edited by admin on Sat Dec 16 10:50:37 GMT 2023
|
PRIMARY | |||
|
71465067
Created by
admin on Sat Dec 16 10:50:37 GMT 2023 , Edited by admin on Sat Dec 16 10:50:37 GMT 2023
|
PRIMARY | |||
|
1402813-38-0
Created by
admin on Sat Dec 16 10:50:37 GMT 2023 , Edited by admin on Sat Dec 16 10:50:37 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
|
PARENT -> SALT/SOLVATE |
|
